<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860481</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2012-09</org_study_id>
    <nct_id>NCT02860481</nct_id>
  </id_info>
  <brief_title>FSH-R : Diagnostic Application for Localized Tumors in Cancerology</brief_title>
  <acronym>FRACTal</acronym>
  <official_title>FSH-R (Follicle-stimulating Hormone Receptor ): Diagnostic Application for Localized Tumors in Cancerology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FRACTal study is the first exploration of detection of FSHR as a blood biomarker for the
      diagnosis of cancer.

      A first cohort will explore several common (e.g. breast, prostate) or rare (e.g. uveal
      melanoma) cancers, that are frequently treated at Institut Curie. This first cohort will
      include n=10 patients per histological type except for breast cancer (n=50). 100 patients are
      expected in this cohort.

      A second cohort will explore the more promising histological type (if any) in term of
      incidence of detection. 100 patients are expected for this second cohort.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no inclusions
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 13, 2017</completion_date>
  <primary_completion_date type="Actual">April 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity of blood FSH R detection in cancer patients</measure>
    <time_frame>end of the study, up to two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>variability of blood FSH-R in the same tumoral type and between different tumoral types</measure>
    <time_frame>end of the study, up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of blood FSH-R with blood from healthy donor</measure>
    <time_frame>end of the study, up to two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>first cohort : first 100 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>first cohort : first 100 patients 10 patients with ovarian and/or endometrial cancer 10 patients with colorectal cancer 10 patients with head and neck cancer 10 patients with uveal melanoma 40 patients with invasive breast cancer 10 patients with breast ductal carcinoma in situ 10 patients with other tumor type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>second cohort : 100 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with breast cancer of with ovarian and/or endometrial cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sample for FSHR analysis</intervention_name>
    <arm_group_label>first cohort : first 100 patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sample for FSHR analysis</intervention_name>
    <arm_group_label>second cohort : 100 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Patient diagnosed with localized cancer and corresponding to the different types
             explored. The cancer can be already diagnosed or not (strong suspicion)

          2. Age&gt; 18

          3. Written informed consent

        Exclusion criteria

          1. Previous treatment for the tumoral disease

          2. Personal history of cancer diagnosis in the last 10 years

          3. Pregnant and/or breastfeeding women

          4. Person deprived of liberty or under guardianship (including curatorship)

          5. psychiatric illness/social situation that would interfere with the protocol or limit
             compliance with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Clément Bidard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

